CV. COVID-19 vaccine surveillance report. Week 4


Recopilado por Carlos Cabrera Lozada. Miembro Correspondiente Nacional, ANM puesto 16. ORCID: 0000-0002-3133-5183. 27/01/2022

Executive summary

Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile, and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination program is built upon the best available evidence. UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration, and academic partners to monitor the COVID-19 vaccination program. Details of the vaccine surveillance strategy are set on the page COVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19 vaccines are continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2)

Deja un comentario

Academia Nacional de Medicina